BioCentury
ARTICLE | Financial News

Avilex debuts to develop compounds for neuropathic pain

April 17, 2013 12:11 AM UTC

Avilex Pharma ApS (Copenhagen, Denmark) debuted with undisclosed seed funding from Novo Seeds to develop small molecule ligands targeting discs large homolog 4 ( DLG4; PSD95) for neurology indications. Avilex's lead compounds -- UCCB01-125 for neuropathic pain and UCCB01-144 for neuroprotection post ischemia -- are in lead optimization phase, with preclinical development for one or both molecules slated to start next half. ...